Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 3/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | LDHA | P00338 | 1/20 | 0.49 |
| ▸ | LDHB | P07195 | 1/20 | 0.49 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | ERN1 | O75460 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7328830 | 0.86 | PDE4A (0.50) | PDE4AKDM4EALDH1A1LMNALDHA | |
| SCHEMBL1116276 | 0.86 | HTRA2 (0.56) | PDE4AKDM4EALDH1A1LMNALDHA | |
| SCHEMBL22126667 | 0.83 | LDHA (0.63) | PDE4AKDM4EALDH1A1LMNALDHA | |
| SCHEMBL7317023 | 0.83 | ALDH1A1 (0.48) | PDE4AKDM4EALDH1A1LMNALDHA | |
| SCHEMBL22126655 | 0.82 | ALDH1A1 (0.60) | PDE4AKDM4EALDH1A1LMNALDHA | |
| SCHEMBL11252888 | 0.80 | PDE4A (0.63) | PDE4AKDM4EALDH1A1NPC1MAPK1 | |
| SCHEMBL11252892 | 0.80 | PDE4A (0.63) | PDE4AKDM4EALDH1A1NPC1MAPK1 | |
| SCHEMBL11710905 | 0.80 | PDE4A (0.63) | PDE4AKDM4EALDH1A1NPC1MAPK1 | |
| SCHEMBL2320172 | 0.78 | KDM4E (0.61) | KDM4EALDH1A1LMNALDHALDHB | |
| SCHEMBL8974039 | 0.77 | ALDH1A1 (0.59) | KDM4EALDH1A1LMNALDHALDHB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050042674-A9 | Common ligand mimics: thiazolidinediones and rhodanines | TRIAD THERAPEUTICS, INC. | 2005-02-24 | — | — | US | disclosed |
| US-20040009526-A1 | Common ligand mimics: thiazolidinediones and rhodanines | YU LIN (US) | 2004-01-15 | — | — | US | disclosed |
| WO-2003072033-A2 | COMMON LIGAND MIMICS: THIAZOLIDINEDIONES AND RHODANINES | TRIAD THERAPEUTICS, INC. (US) | 2003-09-04 | — | — | WO | disclosed |
| US-4439608-A | 2-[2-(5-Phenylfurfurylamino)ethyl]pyridines | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1984-03-27 | — | — | US | disclosed |
| US-4339386-A | 5-[(3,4-Dimethoxyphenyl)or(4-chlorophenyl)]-2-furancarboxaldehyde-O-[(methylamino)carbonyl]oxime | MORTON-NORWICH PRODUCTS, INC. (US) | 1982-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009526-A1 | Common ligand mimics: thiazolidinediones and rhodanines | GPR65, NR2E3, FGFR3 | PDE4A 3341/4885KDM4E 4288/4885ALDH1A1 1216/4885 |
| US-20050042674-A9 | Common ligand mimics: thiazolidinediones and rhodanines | GPR65, NR2E3, FGFR3 | PDE4A 3341/4885KDM4E 4288/4885ALDH1A1 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.